Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Q: What does CUSIP 98422T100 represent in this 13F holders report?

CUSIP 98422T100 is the security identifier for XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q1 2024?

30 institutional investors reported XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q1 2024. Use the holders table for investor-level position and value details.

CUSIP: 98422T100

Q1 2024 13F Holders as of 31 Mar 2024

Security type / class: Equity / Common Stock, par value $0.0001 per share
Total 13F shares: 12,460,895
Total 13F value: $13,460,257
Share change: -3,705,477
SEC-reported price per share: $1.08
Number of holders: 30
Value change: -$2,676,053
Number of buys: 11
Number of sells: 13
Shares outstanding: 6,426,426

Security key

98422T100

Report period

Q1 2024

Institutions

Top holders

XLO full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Xilio Therapeutics, Inc. SEC filings Xilio Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 98422T100

Newer quarter: Q3 2025

Recent filing periods:

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025

Ownership snapshot

Top reported holders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

SV7 Impact Medicine Fund LP

Disclosed value leader

SV7 Impact Medicine Fund LP

Comparable rows

0/15

Latest evidence

08 Feb 2024

3/4/5 13F Highest disclosed value: $2,678,630 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

SV7 Impact Medicine Fund LP has the largest disclosed position value at $2.68M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens SV7 Impact Medicine Fund LP's linked filing trail.

Disclosed position value Top 5

SV7 Impact Medicine Fund LP $2.68M

Bain Capital Life Sciences Invest... $2.33M

James E. Flynn $1.9M

Atlas Venture Fund XI, L.P. $1.76M

TAKEDA PHARMACEUTICAL CO LTD $1.22M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
SV7 Impact Medicine Fund LP	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$2,678,630 3,227,264 shares	—	26 Oct 2021
Bain Capital Life Sciences Investors, LLC	3/4/5 13F 10%+ Owner · Company 3/4/5 13F	— denominator unverified	$2,328,493 2,805,413 shares	—	08 Dec 2021
James E. Flynn	3/4/5 Possible Member of 10% Group, 10%+ Owner 3/4/5	— denominator unverified	$1,898,994 2,287,944 shares	—	26 Oct 2021
Atlas Venture Fund XI, L.P.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$1,762,629 2,754,109 shares	—	08 Feb 2024
TAKEDA PHARMACEUTICAL CO LTD	3/4/5 13F 10%+ Owner · Company 3/4/5 13F	— denominator unverified	$1,224,350 1,475,121 shares	—	26 Oct 2021
RiverVest Venture Fund IV, L.P.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$1,196,399 1,441,444 shares	—	26 Oct 2021

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

12,460,895

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q2 2026 Across Filers

Q2 2026 holders

Q1 2024 holders

Holder diff

Investor	Q2 2026 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q2 2026 value	Q1 2024 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend